People from every walk of life are living healthier, more active lives—thanks to the medical breakthroughs pioneered by American Lung Association researchers and their colleagues worldwide.
Since 1915, our researchers have made significant contributions and achieved major milestones in the fight against lung disease by revolutionizing treatment and unlocking secrets of the body's immune system. Premature babies now are less likely to die from respiratory distress syndrome; tuberculosis (TB) rates are at an all-time low; young and old with chronic lung diseases are benefiting from improved treatment options, including lung transplantation, oxygen therapy, and genetically-based medicines.
Some of our contributions to research include:
1950: Dr. Edith Lincoln, a grantee, observed and reported that isoniazid, the primary medication against TB, prevented the development of serious complications in children such as disseminated tuberculosis and tuberculous meningitis. Later Public Health Service trials underscored isoniazid's important ability to prevent the spread of infection when given to household members of tuberculosis patients.
1959: Dr. Mary Ellen Avery, a grantee, discovered that the lungs of babies with respiratory distress syndrome (RDS) lack the fatty substance, surfactant. This finding led to ways to treat RDS and it’s estimated that more than 800,000 babies’ lives have been saved since then. For her continued investigative work in this field, Dr. Avery was awarded the National Medal of Science in 1991.
1989: Dr. Michael Iannuzzi, a grantee, helped discover the cystic fibrosis gene. Cystic fibrosis is an often fatal lung disease that is the result of a defective gene that causes the body to produce abnormally thick mucus, which clogs the lungs and leads to life-threatening lung infections. Finding this gene opened the door for scientists to develop treatments for cystic fibrosis, including gene therapy.
2001: The Airways Clinical Research Network, released the results of its first study, the Study of Inactivated Influenza Vaccine in Asthmatics, published in the New England Journal of Medicine.This study found that influenza vaccines are safe for both children and adults with asthma. Based on these American Lung Association findings, The Centers for Disease Control and Prevention now recommends flu shots for children with asthma in the Advisory Committee on Immunization Practices of the Centers for Disease Control recommendations and The Healthy People 2020 Goals. Administering the flu vaccine to people with asthma has the potential to majorly reduce hospitalizations and increase cost savings.
Simpler regimen of a once-a-day drug is just as effective as twice-daily treatment for patients with mild persistent asthma
2007: This study, conducted by the Airways Clinical Research Centers Network and published in the New England Journal of Medicine, found that a simpler regimen of a once-a-day combination therapy of inhaled fluticasone plus salmeterol was just as effective as twice-daily treatment of inhaled corticosteroids in patients with mild, persistent asthma. For people with asthma, a simpler treatment plan means fewer drugs to take (and to remember to take) every day and fewer prescription refills. Overall, this reduces medication costs, reduces side effects and makes it easier for people to take their medication as prescribed. For people with asthma who are at least 6 years old and currently using a preventative medication, the use of once-daily fluticasone plus salmeterol, instead of twice-daily fluticasone could save almost $2 billion per year.
2008: Dr. Alan Fields, a grantee at Mayo Clinic Florida, identified a major oncogene that may cause the development of lung cancer and that a drug approved to treat arthritis may function in inhibiting the growth of tumor cells.
Discovered that heartburn medication does not improve asthma in children and adults who do not exhibit symptoms of acid reflux
2008/2012: The Study of Acid Reflux and Asthma (SARA) examined whether there was a connection between asthma and gastroesophageal reflux (GERD). It examined whether treatments for GERD decreased asthma flare-ups in adults and children. The results of this study found the longstanding practice of prescribing heartburn medication to be ineffective and unnecessarily expensive for some asthma patients who do not exhibit symptoms associated with acid reflux such as heartburn or stomach pain. This finding is considered to be the most comprehensive evaluation to date of how effective (or ineffective) prescription heartburn medication is at controlling respiratory flare-ups in people with asthma whose symptoms have not been well controlled by other therapies. Based on results from both these studies, roughly 1.5 million asthma patients may be taking expensive medication unnecessarily.